KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q1 2017 13F Holders as of 31 Mar 2017
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 51,679,622
- Total 13F shares
- 7,587,480
- Share change
- +259,060
- Total reported value
- $59,162,000
- Price per share
- $7.81
- Number of holders
- 18
- Value change
- +$2,023,038
- Number of buys
- 7
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S |
13F
|
Company |
5.6%
|
2,901,927
|
$20,517,000 | — | 31 Dec 2016 | |
| SV Health Investors, LLC |
13F
|
Company |
5%
|
2,579,490
|
$18,237,000 | — | 31 Dec 2016 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
1.1%
|
591,070
|
$4,179,000 | — | 31 Dec 2016 | |
| INTERWEST VENTURE MANAGEMENT CO |
13F
|
Company |
0.64%
|
329,942
|
$2,333,000 | — | 31 Dec 2016 | |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
13F
|
Company |
0.62%
|
322,436
|
$2,186,000 | — | 31 Dec 2016 | |
| Vivo Capital, LLC |
13F
|
Company |
0.58%
|
300,325
|
$2,123,000 | — | 31 Dec 2016 | |
| VHCP Management II, LLC |
13F
|
Company |
0.43%
|
221,651
|
$1,322,000 | — | 31 Dec 2016 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.08%
|
39,296
|
$278,000 | — | 31 Dec 2016 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.03%
|
16,346
|
$116,000 | — | 31 Dec 2016 | |
| FIRST QUADRANT LLC/CA |
13F
|
Company |
0.02%
|
12,750
|
$90,000 | — | 31 Dec 2016 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.02%
|
11,483
|
$81,000 | — | 31 Dec 2016 | |
| BlackRock Fund Advisors |
13F
|
Company |
0%
|
2,274
|
$16,000 | — | 31 Dec 2016 | |
| UBS Group AG |
13F
|
Company |
0%
|
909
|
$6,000 | — | 31 Dec 2016 | |
| BlackRock Institutional Trust Company, N.A. |
13F
|
Company |
0%
|
362
|
$3,000 | — | 31 Dec 2016 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0%
|
310
|
$3,000 | — | 31 Dec 2016 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
263
|
$2,000 | — | 31 Dec 2016 | |
| BLACKROCK ADVISORS LLC |
13F
|
Company |
0%
|
258
|
$2,000 | — | 31 Dec 2016 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
159
|
$1,000 | — | 31 Dec 2016 | |
| Creative Planning |
13F
|
Company |
0%
|
142
|
$1,000 | — | 31 Dec 2016 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q1 2017
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2017 vs Q4 2016 Across Filers
| Investor | Q4 2016 Shares | Q1 2017 Shares | Share Diff | Share Chg % | Q4 2016 Value $ | Q1 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.